Morepen Laboratories surges on launching Desloratadine tablets
Morepen Laboratories is currently trading at Rs. 99.00, up by 4.65 points or 4.93% from its previous closing of Rs. 94.35 on the BSE.
The scrip opened at Rs. 94.35 and has touched a high and low of Rs. 99.05 and Rs. 94.35 respectively. So far 346022 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 2 has touched a 52 week high of Rs. 150.80 on 07-Oct-2026 and a 52 week low of Rs. 33.44 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 107.75 and Rs. 88.10 respectively. The current market cap of the company is Rs. 5424.74 crore.
The promoters holding in the company stood at 35.65%, while Institutions and Non-Institutions held 5.10% and 59.24% respectively.
Morepen Laboratories has launched its first prescription (Rx) generic product, Desloratadine Tablets USP, 5 mg, in 100-count and 500-count packs, for distribution in the U.S. market. The initiative is being undertaken through its wholly owned U.S. arm, Morepen Bio Inc. The company has been supplying Desloratadine API to the U.S. market for many years. Building on this established API position, the latest launch extends the company's participation further along the pharmaceutical value chain into finished-dosage medicines and U.S. distribution.
The prescription generics expansion follows Morepen Laboratories' earlier U.S. OTC product introductions. Separately, the company has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Phosphate Tablets USP, 25 mg, 50 mg and 100 mg. This lunch demonstrates the company's growing capabilities in formulation development, analytical science and regulatory filings. The application is currently under regulatory review.
